PharmaVigilant
today announced the release of I-Accountability, a drug accountability system that efficiently tracks and controls drug inventory and randomization. As trials become larger and more complex, I-Accountability centralizes and automates the drug accountability process, decreasing workload at the sites, improving compliance and drastically advancing study timelines. I-Accountability provides PharmaVigilant with a competitive advantage with the QR code feature, providing clients with immediate access to inventory status through their smartphones.
I-Accountability is easier to use than manual, paper-based tracking. It provides a user-friendly means of randomization, supply management, and ongoing drug monitoring. In terms of patient randomization, I-Accountability replaces phone and paper based randomization methods and automatically retrieves randomization numbers and corresponding details. This process triggers email alerts to notify shippers and other participants of medication requirements throughout the supply chain, keeping the Sponsor aware of all activities.
Once randomization has occurred, I-Accountability automates the collection of the medication by using state of the art technology to generate QR Codes for each medical product. This allows a ‘Mobile’ interface to interact with the system, so that once the drug is received at the site, any smartphone QR Code App can scan the barcodes to automatically record the receipt and product condition.
Upon drug administration at the site, clinicians receive and enter information concerning dispensation and usage into the EDC system, creating an interoperable feedback cycle that drives the replenishment process. In the event of a damaged product, I-Accountability provides the creation of reorder requests, reducing the amount of time for site staff to conduct tasks.
“I-Accountability offers clients a complete life-cycle service for their clinical trial medications,” says James DeSanti, President and CEO, PharmaVigilant. “In seconds, Sponsors can view a summary of inventory tracking information in I-Accountability globally. With trials containing thousands of subjects across multiple sites/countries in need of study drugs or placebos, immediate access to this information is crucial in order to manage the drug/asset supply chain. We have incorporated QR code functionality to leverage mobile hardware already existent in the field. Smartphones are everywhere, so adding QR codes to medical products will streamline the shipping and receiving process, giving PharmaVigilant a competitive advantage.”
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.